-
At the 57th annual meeting of the Aamerican Society of Tropical Medicine and Hygiene in New Orleans, held from December 7-11, 2008, the CDC presented malaria and travel vaccine updates. Dr. Paul Arguin from the Domestic Malaria Unit presented "Malaria Update: Surveillance, Prevention, Treatment."
-
The Merck integrase inhibitor, raltegravir, was studied in two identical trials in different geographic locations to evaluate its safety and efficacy vs placebo in combination with optimized background therapy in patients infected with 3-drug class-resistant (3DCR) HIV-1.
-
Nucleic acid tests (NAA) for the diagnosis of pulmonary tuberculosis (TB) have had FDA approval for more than a decade, but their use has been limited, at least in part because of a frequent lack of availability in local laboratories.
-
In light of continuing outbreaks of hepatitis in ambulatory and long-term care, the Centers for Disease Control and Prevention is considering recommending hepatitis B virus vaccination for diabetic residents of nursing homes.
-
Once thought of as shocking outliers, the continuing hepatitis outbreaks in ambulatory care settings and clinics increasingly suggest that for every cluster detected, many more infections acquired in health care are being missed due to inadequate surveillance systems and lack of public health resources to investigate individual cases.
-
-
In this issue: FDA warning on topical anesthetics; antipsychotics increase sudden cardiac death; the step up vs step down debate; treating pain, fatigue, mood, and sleep in fibromyalgia; FDA Actions.
-
-
Influenza activity has been relatively low thus far in the 2008-2009 season in the United States. However, of the influenza viruses isolated and tested to date, there is significant resistance among the influenza A (H1N1) viruses to the antiviral oseltamivir.
-
For this study, 12,765 patients from the large French Hospital Database for HIV with CD4+ lymphocyte counts < 200 cells/uL who received cART during 2000-2005 were selected.